ArticleMolecular pharmacology2017
Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Hexahydrocannabinol (HHC) and ΔScientific reports · 2024Article
- Limited WKY chromosomal regions confer increases in anxiety and fear memory in a F344 congenic rat strain.Physiological genomics · 2024Article
- Mechanisms of cannabinoid tolerance.Biochemical pharmacology · 2023Review
- SGIP1 in axons prevents internalization of desensitized CB1R and modifies its function.Frontiers in neuroscience · 2023Review
- Developing Photoaffinity Probes for Dopamine Receptor DACS chemical neuroscience · 2022Article
- Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CBMicrobial cell factories · 2022Article
- Acute and long-term effects of cannabinoids on hypertension and kidney injury.Scientific reports · 2022Article
- SGIP1 modulates kinetics and interactions of the cannabinoid receptor 1 and G protein-coupled receptor kinase 3 signalosome.Journal of neurochemistry · 2022Article
- Functional Selectivity of a Biased Cannabinoid-1 Receptor (CBACS pharmacology & translational science · 2021Article
- Review of the Endocannabinoid System.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2021Review
- Targeting Endocannabinoid Signaling in the Lateral Habenula as an Intervention to Prevent Mental Illnesses Following Early Life Stress: A Perspective.Frontiers in synaptic neuroscience · 2021Article
- Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease.Biomolecules · 2020Review
- Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R).Frontiers in molecular neuroscience · 2020Review
- Molecular Interaction between Distal C-Terminal Domain of the CBJournal of chemical information and modeling · 2019Article
- G protein-coupled receptors in acquired epilepsy: Druggability and translatability.Progress in neurobiology · 2019Review
- Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure.Molecules (Basel, Switzerland) · 2019Review
- CB1 cannabinoid receptor-phosphorylated fourth intracellular loop structure-function relationships.Peptide science (Hoboken, N.J.) · 2019Article
- Article
- Structural Insights into CB1 Receptor Biased Signaling.International journal of molecular sciences · 2019Review
- Translational potential of allosteric modulators targeting the cannabinoid CBActa pharmacologica Sinica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Lawrence C BlumeDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Theresa PattenDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Khalil EldeebDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Sandra Leone-KablerDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Alexander A IlyasovDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Bradley M KeeganDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Jeremy E O'NealDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Caroline E BassDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Roy R HantganDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
W Todd LowtherDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
Dana E SelleyDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.).
A Llyn C HowlettDepartment of Physiology and Pharmacology (L.C.B., T.P, K.E., S.L.-K., A.A.I., B.M.K., J.E.O., C.E.B., A.C.H.) and Department of Biochemistry and Center for Structural Biology (R.R.H., W.T.L.), Wake Forest University Health Sciences, Winston-Salem, North Carolina; Department of Chemistry (T.P.) and Center for Molecular Signaling (W.T.L., A.C.H.), Wake Forest University, Winston-Salem, North Carolina; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (D.E.S.); and AL Azhar Faculty of Medicine, New Damietta, Egypt (K.E.) ahowlett@wakehealth.edu.
Wake Forest University · USVirginia Commonwealth University · US
Funding
Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4MTROPANE EVALUATION AND GENERAL SCIENTIFIC SERVICES COREP50DA006634 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI PORRINO, LINDA J. · 1991 to 2019
$30.8MMULTI-DISCIPLINARY TRAINING IN THE BIOLOGY OF ALCOHOLISMT32AA007565 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BRIAN A MCCOOL · 1994 to 2026
$10.1MWake Forest University School of Medicine PREP ScholarsR25GM064249 · NIGMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DIZ, DEBRA I · 2001 to 2017
$4.8MCANNABINOID RECEPTORS IN NEURONAL CELLS AND BRAINR01DA003690 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HOWLETT, ALLYN C · 1985 to 2014
$2.8MPostdoctoral Research, Instruction, and Mentoring Experience (PRIME)K12GM102773 · NIGMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HOWLETT, ALLYN C · 2013 to 2018
$2.6MNEUROSCIENCE OF DRUG ABUSE TRAINING PROGRAMT32DA007246 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CHILDERS, STEVEN R · 1991 to 2011
$2.2MCB1 and DA Receptor Deletion by RNAi in Cocaine Self-AdministrationK01DA024763 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BASS, CAROLINE EVELYN · 2008 to 2011
$568kCB1 Receptor Regulation by Cannabinoid Receptor Interacting Protein CRIP1aR21DA025321 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HOWLETT, ALLYN C, SELLEY, DANA E · 2009 to 2010
$420kFunctional studies of cannabinoid receptor-interacting protein 1a in null miceR03DA035424 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI SELLEY, DANA E · 2014 to 2015
$151kCannabinoid Receptor Interacting Protein1a Structure-FunctionF31DA032215 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLUME, LAWRENCE CHRISTOPHER · 2012 to 2013
$83kNCI NIH HHS P30 CA012197NIAAA NIH HHS T32 AA007565NIDA NIH HHS F31 DA032215NIDA NIH HHS K01 DA024763NIDA NIH HHS P50 DA006634NIDA NIH HHS R01 DA003690NIDA NIH HHS R03 DA035424NIDA NIH HHS R21 DA025321NIDA NIH HHS T32 DA007246NIGMS NIH HHS K12 GM102773NIGMS NIH HHS R25 GM064249
Abstract
Cannabinoid receptor interacting protein 1a (CRIP1a) is a CB
Indexed as
Amino Acid SequenceAnimalsbeta-ArrestinsCarrier ProteinsCell Line, TumorGreen Fluorescent ProteinsHumansMembrane ProteinsPeptidesPhosphorylationProtein BindingRatsReceptor, Cannabinoid, CB1beta-ArrestinsCarrier ProteinsCNRIP1 protein, humanCnrip1 protein, ratGreen Fluorescent ProteinsMembrane ProteinsPeptidesReceptor, Cannabinoid, CB1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.